Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8000759 | 0.77 | POLB (0.56) | POLBADRA1DMEN1KMT2AGAA | |
| SCHEMBL18197636 | 0.76 | KCNH2 (0.35) | POLBADRA1DPNMTKCNH2 | |
| SCHEMBL11987816 | 0.76 | POLB (0.59) | POLBADRA1DMEN1KMT2AKDM4E | |
| SCHEMBL11987826 | 0.76 | POLB (0.59) | POLBADRA1DMEN1KMT2AKDM4E | |
| SCHEMBL19441931 | 0.73 | KCNH2 (0.35) | POLBKCNH2 | |
| SCHEMBL22502985 | 0.71 | PNMT (0.43) | PNMT | |
| SCHEMBL24627475 | 0.65 | HTR2C (0.52) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL19406888 | 0.65 | PNMT (0.39) | CYP2C9PNMTKCNH2 | |
| SCHEMBL16519854 | 0.64 | POLB (0.53) | POLBADRA1DMEN1KMT2AGAA | |
| Morpholine SCHEMBL456806 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | POLB 2699/4885ADRA1D 2536/4885MEN1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.